These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 32568111)

  • 1. Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial.
    Hommel ALAJ; Meinders MJ; Weerkamp NJ; Richinger C; Schmotz C; Lorenzl S; Dodel R; Coelho M; Ferreira JJ; Tison F; Boraud T; Meissner WG; Rosqvist K; Timpka J; Odin P; Wittenberg M; Bloem BR; Koopmans RT; Schragand A;
    J Parkinsons Dis; 2020; 10(3):1171-1184. PubMed ID: 32568111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
    Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
    Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease motor subtypes and bilateral GPi deep brain stimulation: One-year outcomes.
    Tsuboi T; Lemos Melo Lobo Jofili Lopes J; Patel B; Legacy J; Moore K; Eisinger RS; Almeida L; Foote KD; Okun MS; Ramirez-Zamora A
    Parkinsonism Relat Disord; 2020 Jun; 75():7-13. PubMed ID: 32428801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of bilateral subthalamic stimulation on alexithymia in Parkinson's disease.
    Dafsari HS; Ray-Chaudhuri K; Mahlstedt P; Sachse L; Steffen JK; Petry-Schmelzer JN; Dembek TA; Reker P; Barbe MT; Visser-Vandewalle V; Fink GR; Timmermann L
    Eur J Neurol; 2019 Feb; 26(2):222-e17. PubMed ID: 30107062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated multidisciplinary care in Parkinson's disease: a non-randomised, controlled trial (IMPACT).
    van der Marck MA; Munneke M; Mulleners W; Hoogerwaard EM; Borm GF; Overeem S; Bloem BR;
    Lancet Neurol; 2013 Oct; 12(10):947-56. PubMed ID: 23988337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease.
    Schrag A; Selai C; Jahanshahi M; Quinn NP
    J Neurol Neurosurg Psychiatry; 2000 Jul; 69(1):67-73. PubMed ID: 10864606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
    Tison F; Yekhlef F; Chrysostome V; Balestre E; Quinn NP; Poewe W; Wenning GK
    Mov Disord; 2002 Jul; 17(4):701-9. PubMed ID: 12210859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of Patients with Late-Stage Parkinsonism Who are Nursing Home Residents Compared with those Living at Home.
    Hosking A; Hommel AALJ; Lorenzl S; Coelho M; Ferreira JJ; Meissner WG; Odin P; Bloem BR; Dodel R; Schrag A;
    J Am Med Dir Assoc; 2021 Feb; 22(2):440-445.e2. PubMed ID: 32723531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson's disease.
    Dafsari HS; Dos Santos Ghilardi MG; Visser-Vandewalle V; Rizos A; Ashkan K; Silverdale M; Evans J; Martinez RCR; Cury RG; Jost ST; Barbe MT; Fink GR; Antonini A; Ray-Chaudhuri K; Martinez-Martin P; Fonoff ET; Timmermann L;
    Brain Stimul; 2020; 13(6):1697-1705. PubMed ID: 33038595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal Pressure Hydrocephalus and Parkinsonism: Preliminary Data on Neurosurgical and Neurological Treatment.
    Broggi M; Redaelli V; Tringali G; Restelli F; Romito L; Schiavolin S; Tagliavini F; Broggi G
    World Neurosurg; 2016 Jun; 90():348-356. PubMed ID: 26970480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which Scale Best Detects Treatment Response of Tremor in Parkinsonism?
    Pintér D; Forjaz MJ; Martinez-Martin P; Rodriguez-Blazquez C; Ayala A; Juhász A; Harmat M; Janszky J; Kovács N
    J Parkinsons Dis; 2020; 10(1):275-282. PubMed ID: 31868685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caregiver Burden in Late-Stage Parkinsonism and Its Associations.
    Kalampokini S; Hommel ALAJ; Lorenzl S; Ferreira JJ; Meissner WG; Odin P; Bloem BR; Dodel R; Schrag AE
    J Geriatr Psychiatry Neurol; 2022 Jan; 35(1):110-120. PubMed ID: 33094677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
    Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
    J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomised controlled trial (PD REHAB).
    Clarke CE; Patel S; Ives N; Rick CE; Woolley R; Wheatley K; Walker MF; Zhu S; Kandiyali R; Yao G; Sackley CM
    Health Technol Assess; 2016 Aug; 20(63):1-96. PubMed ID: 27580669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
    Cattaneo C; Jost WH; Bonizzoni E
    J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vastly Different Exercise Programs Similarly Improve Parkinsonian Symptoms: A Randomized Clinical Trial.
    Tollár J; Nagy F; Hortobágyi T
    Gerontology; 2019; 65(2):120-127. PubMed ID: 30368495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Key Determinants to Quality of Life in Parkinson's Disease Patients: Results from the Parkinson's Disease Biomarker Program (PDBP).
    He L; Lee EY; Sterling NW; Kong L; Lewis MM; Du G; Eslinger PJ; Huang X
    J Parkinsons Dis; 2016 May; 6(3):523-32. PubMed ID: 27258700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.